Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04476225 · ClinicalTrials.gov registry record
Induced Pluripotent Stem Cells for Disease Research
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 1
- Enrollment target
NCT04476225: Completed study, sponsored by University of California, San Francisco.
NCT04476225 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04476225 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 1 participants
- Enrollment target
Study Summary
The aim of this study is to determine the contribution of genetic factors to the pathogenesis of diseases, including diseases such as Parkinson's disease, Hirschsprung's disease, and autism. Patient-derived cellular models of diseases will be developed, which will require the collection of blood samples from patients and healthy individuals in order to generate induced pluripotent stem cells (iPSCs) for the development of iPSC-derived human cell cultures. These human cellular models will be phenotyped using a variety of methods, including cellular, molecular, and biochemical assays. Because these human cellular models will retain the genetic background from the patients and control subjects, this will allow us to determine the contribution of genetics to disease phenotypes. Such disease-specific pluripotent stem cell lines will be invaluable tools for many basic and translational research applications, including pathophysiological studies in a developmental context, and innovation and screening of small molecule drugs capable of reversing the disease phenotype and potentially leading to a cure for a broad range of diseases, where appropriate in vitro or in vivo disease models do not exist.
Primary Outcome
Collect human peripheral blood mononuclear cells (PBMCs) and reprogram into iPSCs.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-04-15 |
| Est. Completion | 2022-10-03 |
What the finished NCT04476225 record still lists
NCT04476225 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 1 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04476225 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04476225 about?
NCT04476225 is a clinical study titled "Induced Pluripotent Stem Cells for Disease Research". The aim of this study is to determine the contribution of genetic factors to the pathogenesis of diseases, including diseases such as Parkinson's disease, Hirschsprung's disease, and autism. Patient-derived cellular models of diseases will be developed, which will require the collection of blood sam...
What is the current status of trial NCT04476225?
This trial is currently completed. The enrollment target is 1 participants. The study started on 2022-04-15. Estimated completion is 2022-10-03.
Who is sponsoring clinical trial NCT04476225?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI